ACTRN12618000055202p: A study of the safety and effectiveness of Lipegfilgrastim, a growth factor, to prevent fever and infections ('febrile neutropenia') in patients undergoing chemotherapy for Non-Hodgkin Lymphoma (NHLL) |
|
|
| Not yet recruiting | 4 | 30 | | | Monash Health, TEVA pharmaceuticals | Non-Hodgkin Lymphoma | | | | |
ACTRN12618000055202: A study of the safety and effectiveness of Lipegfilgrastim, a growth factor, to prevent fever and infections ('febrile neutropenia') in patients undergoing chemotherapy for Non-Hodgkin Lymphoma (NHLL) |
|
|
| Not yet recruiting | 4 | 30 | | | Monash Health, TEVA pharmaceuticals | Non-Hodgkin Lymphoma | | | | |
2015-000087-34: Clinical trial comparing Lipegfilgrastim to Filgrastim in Pediatric Patients Diagnosed with Ewing Family of Tumors or Rhabdomyosarcoma Receiving Chemotherapy. Vizsgálat a lipegfilgrastim kezelés összehasonlítására a filgrastim kezeléssel, Ewing tumorok családjába tartozó betegséggel, vagy rhabdomioszarkómával diagnosztizált és kemoterápiával kezelt gyermek betegekben |
|
|
| Ongoing | 2 | 42 | Europe, RoW | Lipegfilgrastim, Neupogen, XM22, Solution for injection, LONQUEX, Neupogen 30 MU (0.3 mg/ml) solution for injection | Merckle GmbH, Merckle GmbH | Neutropenia in pediatric patients diagnosed with Ewing family of Tumors or rhabdomyosarcoma receiving chemotherapy Neutropénia Ewing tumorok családjába tartozó betegséggel, vagy rhabdomioszarkómával diagnosztizált és kemoterápiával kezelt gyermek betegekben, treatment of chemotherapy induced neutropenia (white blood cell decrease) a kemoterápia okozta neutropenia (a fehérvérsejtek csökkenése), Diseases [C] - Blood and lymphatic diseases [C15] | | | | |